Sharps Technology (STSS) said Wednesday it has initiated first shipments of its SecureGard and SoloGard smart safety syringes relating to three client orders from its manufacturing site in Hungary.
The company began shipment of its first commercial order of Sologard to a US-based IV flushing services provider under a previously announced $50 million agreement, while it has also delivered SecureGard syringes to a Hungarian vaccine provider after securing a $100,000 purchase order, Sharps said.
The total purchase commitments reached roughly $500,000 with the two orders, the company said.
The medical device and pharmaceutical packaging company also said it started a 200,000-unit shipment of 1mL low dead-volume syringes to a Switzerland-based global provider of cosmetic, dental, and ophthalmic injectable therapies.
Shares were up more than 53% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.